[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ziady et al., 2004 - Google Patents

Defining strategies to extend duration of gene expression from targeted compacted DNA vectors

Ziady et al., 2004

View PDF
Document ID
8740378431553498666
Author
Ziady A
Kim J
Colla J
Davis P
Publication year
Publication venue
Gene therapy

External Links

Snippet

Gene transfer complexes containing poly-L-lysine (poly-K) and DNA with ligands directed at the serpin enzyme complex receptor (sec-R) deliver reporter genes to receptor-bearing cells in vivo. Expression lasts for about 30 days, when complexes containing long-chain poly-K …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Similar Documents

Publication Publication Date Title
Kawabata et al. Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth
Kren et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice
Zou et al. Systemic linear polyethylenimine (L‐PEI)‐mediated gene delivery in the mouse
Buch et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration
US6077835A (en) Delivery of compacted nucleic acid to cells
US6008336A (en) Compacted nucleic acids and their delivery to cells
US5844107A (en) Compacted nucleic acids and their delivery to cells
Ferkol et al. Receptor-mediated gene transfer into macrophages.
Fan et al. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease
JP6018069B2 (en) Methods and compositions for treating hemophilia B
ES2895430T3 (en) Methods and compositions for the treatment of neurological disease
Biglari et al. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model
US20060228404A1 (en) Compositions and methods for treatment of hypertrophic tissues
JP2010031023A (en) Composition and method for treating lysosomal storage disease
BR112020021962A2 (en) constructs for gene therapy and methods of use
ES2905791T3 (en) Engineered Nucleases Useful for Treatment of Hemophilia A
KR20210133993A (en) CRISPR/RNA-guided nuclease-related methods and compositions for treating RHO-associated autosomal-dominant retinitis pigmentosa (ADRP)
BR112020009268A2 (en) crispr distribution platforms targeted
Yin et al. Appropriate delivery of the CRISPR/Cas9 system through the nonlysosomal route: Application for therapeutic gene editing
Zheng et al. mRNA‐Loaded Lipid‐Like Nanoparticles for Liver Base Editing Via the Optimization of Central Composite Design
Griesenbach et al. Advances in cystic fibrosis gene therapy
Liu et al. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer
Anderson et al. Ultrasound-targeted hepatic delivery of factor IX in hemophiliac mice
Ziady et al. Defining strategies to extend duration of gene expression from targeted compacted DNA vectors
Bouchard et al. Long‐term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno‐associated viral vectors in mice